Cargando…

Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease

BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yun, Lin, Junfeng, Wang, Zihui, Wang, Zhufeng, Tan, Lunfang, Liu, Shuyi, Huang, Jinhai, Gao, Yi, Zheng, Jinping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586173/
https://www.ncbi.nlm.nih.gov/pubmed/36274994
http://dx.doi.org/10.2147/COPD.S385733
_version_ 1784813639916584960
author Li, Yun
Lin, Junfeng
Wang, Zihui
Wang, Zhufeng
Tan, Lunfang
Liu, Shuyi
Huang, Jinhai
Gao, Yi
Zheng, Jinping
author_facet Li, Yun
Lin, Junfeng
Wang, Zihui
Wang, Zhufeng
Tan, Lunfang
Liu, Shuyi
Huang, Jinhai
Gao, Yi
Zheng, Jinping
author_sort Li, Yun
collection PubMed
description BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore the differences between the 2005 and 2021 ERS/ATS criteria applied to patients with asthma as well as chronic obstructive pulmonary disease (COPD). METHODS: BDR test data about asthma patients aged 6–80 years and COPD patients aged 18–80 years were derived from the National Respiratory Medicine Center, First Affiliated Hospital of Guangzhou Medical University, from January 2017 to March 2022. BDR results defined by the 2005 and 2021 ERS/ATS criteria were named 2005-BDR and 2021-BDR, respectively. We compared differences between 2005-BDR and 2021-BDR and analyzed the trend in the proportion of positive BDR (BDR+) with the level of airflow obstruction. RESULTS: A total of 4457 patients with asthma and 7764 patients with COPD were included in the analysis. The percentages of 2005-BDR+ and 2021-BDR+ were 63.32% and 52.84% for asthma, 30.92% and 22.94% for COPD, respectively. Of patients with 2005-BDR+, 81.86% for asthma and 70.18% for COPD showed 2021-BDR+ results, and these patients had higher FEV(1)%pred, FVC%pred (all P<0.05). Whichever BDR criterion was adopted, the proportion of BDR+ had an upward linear trend with the increased degree of airflow obstruction in COPD, but exhibited an approximate inverted U-shaped curve in asthma. In COPD, the proportion of BDR(FEV1) was negatively associated with the degree of airflow obstruction, while BDR(FVC) was positively associated (all P<0.05). CONCLUSION: Compared with 2005-BDR+, the proportion of 2021-BDR+ reduced markedly in patients with asthma and COPD, but their trends with the degree of airflow obstruction did not change. Patients with consistent BDR+ had higher initial FEV(1)%pred and FVC%pred.
format Online
Article
Text
id pubmed-9586173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95861732022-10-22 Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease Li, Yun Lin, Junfeng Wang, Zihui Wang, Zhufeng Tan, Lunfang Liu, Shuyi Huang, Jinhai Gao, Yi Zheng, Jinping Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore the differences between the 2005 and 2021 ERS/ATS criteria applied to patients with asthma as well as chronic obstructive pulmonary disease (COPD). METHODS: BDR test data about asthma patients aged 6–80 years and COPD patients aged 18–80 years were derived from the National Respiratory Medicine Center, First Affiliated Hospital of Guangzhou Medical University, from January 2017 to March 2022. BDR results defined by the 2005 and 2021 ERS/ATS criteria were named 2005-BDR and 2021-BDR, respectively. We compared differences between 2005-BDR and 2021-BDR and analyzed the trend in the proportion of positive BDR (BDR+) with the level of airflow obstruction. RESULTS: A total of 4457 patients with asthma and 7764 patients with COPD were included in the analysis. The percentages of 2005-BDR+ and 2021-BDR+ were 63.32% and 52.84% for asthma, 30.92% and 22.94% for COPD, respectively. Of patients with 2005-BDR+, 81.86% for asthma and 70.18% for COPD showed 2021-BDR+ results, and these patients had higher FEV(1)%pred, FVC%pred (all P<0.05). Whichever BDR criterion was adopted, the proportion of BDR+ had an upward linear trend with the increased degree of airflow obstruction in COPD, but exhibited an approximate inverted U-shaped curve in asthma. In COPD, the proportion of BDR(FEV1) was negatively associated with the degree of airflow obstruction, while BDR(FVC) was positively associated (all P<0.05). CONCLUSION: Compared with 2005-BDR+, the proportion of 2021-BDR+ reduced markedly in patients with asthma and COPD, but their trends with the degree of airflow obstruction did not change. Patients with consistent BDR+ had higher initial FEV(1)%pred and FVC%pred. Dove 2022-10-17 /pmc/articles/PMC9586173/ /pubmed/36274994 http://dx.doi.org/10.2147/COPD.S385733 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Yun
Lin, Junfeng
Wang, Zihui
Wang, Zhufeng
Tan, Lunfang
Liu, Shuyi
Huang, Jinhai
Gao, Yi
Zheng, Jinping
Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title_full Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title_fullStr Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title_full_unstemmed Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title_short Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
title_sort bronchodilator responsiveness defined by the 2005 and 2021 ers/ats criteria in patients with asthma as well as chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586173/
https://www.ncbi.nlm.nih.gov/pubmed/36274994
http://dx.doi.org/10.2147/COPD.S385733
work_keys_str_mv AT liyun bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT linjunfeng bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT wangzihui bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT wangzhufeng bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT tanlunfang bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT liushuyi bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT huangjinhai bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT gaoyi bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease
AT zhengjinping bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease